Middle-Income Countries consider voiding hepatitis C drug patents

Physician, patient, and health justice groups including the Initiative for Medicines, Access and Knowledge (I-MAK) are mounting legal challenges to Gilead Sciences' patent to sofosbuvir in several middle-income countries including Argentina, Brazil, China, Russia and Ukraine. Read more...http://www.nytimes.com/2015/05/20/business/high-cost-of-hepatitis-c-drug-prompts-a-call-to-void-its-patents.html...

REQUEST: Patient input for BC Pharmacare RE: HOLKIRA PAK™

BC PharmaCare has issued a call for Patient Input into whether they should cover AbbVie's new hepatitis C treatment, HOLKIRA PAK™ (ombitasvir, paritaprevir, ritonavir, and dasabuvir [±ribavirin]).HepCBC is going to make a submission to BC PharmaCare, and URGENTLY requests input from those who have, or have ever had hepatitis C (and their caregivers). Our submission is only as good as the input we get from people like you!You would have to answer a few ques

Hepatitis C Elimination Experiment Launched in Georgia

Eastern Europe's Republic of Georgia, with a population of 5 million - of which 7% has hepatitis C - has approximately 350,000 HCV+ people, similar to the number with the disease in Canada. The country, with minimal resources for fighting such an epidemic, has teamed up with the maker of SOVALDI and HARVONI to attempt to demonstrate that, with careful planning and using new hepatitis C drugs, hepatitis C can be eliminated. The company, Gilead, is providing

Why CADTH needs Patient Group Input from HepCBC

Patient Groups such as HepCBC  provide patient input to the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Canadian Drug Review (CDR) which helps them determine whether they should approve drugs for use in Canada, and what restrictions and criteria should be applied to their use. Here are some new (SHORT but GREAT!) YouTube videos which show why this input is so critical, and how it is used to benefits patients such as US! CLICK HERE

In Praise of Stand-Alone HCV Drugs

BMS recently withdrew its US FDA application for the hepatitis C drug, asunaprevir. It is probably a very wise decision on BMS' part, because asunaprevir is close in formulation and results to several other generation 2 NS3 protease inhibitors*. Instead, BMS seems to be focusing on its more unique product, the NS5A replication complex inhibitor, daclatasvir, of which they say in their Oct. 7 press release, is "currently being investigated globally in multi

Sofosbuvir & Ledipasvir price pact for low income countries announced by Gilead

Gilead signs hepatitis C drug (sofosbuvir - SOVALDI and ledipasvir) pact to make treatment available in low income countries (Reuters, Sept. 15, 2014) "U.S. drugmaker Gilead Sciences Inc GILD.O has licensed its hepatitis C drug Sovaldi to seven India-based drugmakers that will sell far cheaper versions of the $1,000-a-pill medicine in 91 developing nations...Gilead said it would also launch its own branded Sovaldi in India at a price of $300 a month. The...

PDF of WEBINAR about SOFOSBUVIR and LEDIPASVIR COMBO – Dr. Paul Marotta, Sept. 8, 2014

On Sept. 8, 2014, Dr. Paul Marotta of London Health Sciences Centre, presented "Transformation of HCV Management: The IFN-free Era". To access a PDF of this highly-informative and "up-to-the-minute" presentation, click HERE: DrPaulMarotta_20140908_HCV_Treatment_Presentation. Many thanks, Dr. Marotta, for generously sharing these excellent materials with HepCBC's online members.

New Analysis of Burden of Untreated Hepatitis C in Canada

Canada's top liver physicians released new figures showing dramatically increased costs due to untreated hepatitis C which would place a great burden on our medical system over the next 20 years. Liver-related deaths due to liver cancer, liver failure and other causes due to untreated hepatitis C are projected to increase 160% over the next 20 years, significantly more than projected currently by the Public Health Agency of Canada.  Treatments are availabl